Saxenda Side Effects: Potentially Permanent Adverse Events Explained

Which Saxenda side effects can be permanent?

Gallbladder removal is the documented lasting outcome (see the gallbladder section below) [1]. Fatal pancreatitis has also been reported with liraglutide [1]. The label warns about pancreatitis and acute kidney injury but does not establish how often either leaves lasting damage [1]. Whether Saxenda causes thyroid C-cell tumors in people is unknown [1].

Nausea declined as treatment continued in the adult trials [1]. Hair loss appears in the label only as a postmarketing skin reaction, with frequency not established [1].

Rates for the common reactions come from five placebo-controlled adult trials: 3,384 people taking Saxenda and 1,941 taking placebo, treatment up to 56 weeks, 3 mg daily [1]. Nausea occurred in 39.3% vs 13.8%, diarrhea in 20.9% vs 9.9%, constipation in 19.4% vs 8.5%, vomiting in 15.7% vs 3.9% and dyspepsia in 9.6% vs 2.7% [1]. About 68% vs 39% reported any gastrointestinal disorder, and 9.8% vs 4.3% stopped treatment because of an adverse reaction, most often nausea (2.9% vs 0.2%) [1].

Acute pancreatitis

Acute pancreatitis, including fatal and non-fatal hemorrhagic or necrotizing pancreatitis, has been reported with liraglutide [1]. The 2024 label reports that in the adult Saxenda trials, pancreatitis confirmed by adjudication occurred in 9 of 3,291 Saxenda-treated patients (0.3%) and 2 of 1,843 placebo-treated patients (0.1%) [2].

The label says to watch for persistent or severe abdominal pain, sometimes radiating to the back and possibly accompanied by nausea or vomiting, and to discontinue Saxenda and start appropriate management if pancreatitis is suspected [1].

Acute gallbladder disease and cholecystectomy

In the adult trials, 2.2% of Saxenda-treated patients reported cholelithiasis versus 0.8% of placebo-treated patients, and cholecystitis occurred in 0.8% versus 0.4% [1]. Most Saxenda-treated patients with these gallbladder events required cholecystectomy, removal of the gallbladder [1]. Rapid or substantial weight loss can raise gallstone risk by itself, but the label states that gallbladder events were still more frequent on Saxenda than placebo after accounting for the degree of weight loss [1]. If cholelithiasis is suspected, the label calls for gallbladder studies and appropriate clinical follow-up [1].

Acute kidney injury from dehydration

The label warns about acute kidney injury due to volume depletion and says to monitor renal function in patients who report reactions that could lead to volume depletion [1]. Earlier labeling described postmarketing reports of renal impairment, usually in association with nausea, vomiting, diarrhea or dehydration, sometimes requiring hemodialysis, and advised caution when starting or escalating the dose in people with renal impairment [2].

Thyroid C-cell tumors

Liraglutide caused dose- and duration-dependent thyroid C-cell tumors in both sexes of rats and mice at clinically relevant exposures, and malignant C-cell carcinomas were detected in both species [1]. It is unknown whether Saxenda causes thyroid C-cell tumors, including medullary thyroid carcinoma, in humans; the label states that the human relevance of the rodent findings has not been determined [1]. Cases of MTC in liraglutide-treated patients have been reported after marketing, but the label says the data are insufficient to establish or exclude a causal relationship [1].

A personal or family history of MTC or Multiple Endocrine Neoplasia syndrome type 2 is a contraindication to Saxenda [1]. The label describes routine serum calcitonin monitoring or thyroid ultrasound as of uncertain value for early detection and notes that such monitoring may increase the risk of unnecessary procedures [1]. Significantly elevated calcitonin may indicate MTC, and patients with MTC usually have calcitonin values above 50 ng/L [1]. The label directs that patients be counseled about symptoms of thyroid tumors: a mass in the neck, difficulty swallowing, shortness of breath, persistent hoarseness [1].

Heart rate increase

Resting heart rate rose by a mean of 2 to 3 bpm in Saxenda-treated adults compared with placebo [1]. More Saxenda patients had a change from baseline above 10 bpm at two consecutive visits (34% vs 19%) and above 20 bpm (5% vs 2%); at least one reading above 100 bpm was recorded in 6% vs 4%, and tachycardia was reported as an adverse reaction in 0.6% vs 0.1% [1]. The label lists heart rate increase as a warning and says to monitor heart rate at regular intervals [1].

Severe gastrointestinal reactions and aspiration during procedures

Saxenda use is associated with gastrointestinal adverse reactions, sometimes severe, and the label does not recommend it in patients with severe gastroparesis [1]. Pulmonary aspiration during general anesthesia or deep sedation has been reported in patients receiving GLP-1 receptor agonists, and the label says patients should inform health care providers of any planned surgery or procedure [1].

Suicidal thoughts: what changed in 2026

On 13 January 2026 the FDA asked the makers of Saxenda, Wegovy and Zepbound to remove the suicidal ideation and behavior language from their labels, after a review that included a meta-analysis of 91 placebo-controlled GLP-1 receptor agonist trials (107,910 patients: 60,338 on a GLP-1 drug, 47,572 on placebo) and a claims cohort of 2,243,138 new users found no increased risk [3]. The Saxenda label effective 25 February 2026 no longer contains a suicidal behavior and ideation warning; the version dated 26 January 2024 did [1][2].

Depression still appears in the pediatric trial table, reported by 4% on Saxenda versus 2.4% on placebo among patients aged 12 to 17 [1]. In the 56-week adolescent trial of 251 participants, one suicide occurred in the liraglutide group and was judged by the investigator as unlikely related to treatment [4].

Serious allergic reactions

Anaphylactic reactions and angioedema have been reported after marketing, and serious hypersensitivity to liraglutide or any excipient in Saxenda is a contraindication [1].

Who should not take Saxenda

Saxenda is contraindicated in patients with a personal or family history of MTC or MEN 2 and in patients with a serious hypersensitivity reaction to liraglutide or to any excipient in Saxenda [1]. Pregnancy is treated differently in the current label than in the 2024 version: the 2024 label listed pregnancy as a contraindication [2], while the label effective 25 February 2026 says Saxenda should be used during pregnancy only if the potential benefit justifies the potential risk to the fetus, that weight loss offers no benefit in pregnancy, and that Saxenda should be discontinued when pregnancy is recognized [1].

Stopping Saxenda

For adults, the label directs that weight be evaluated 16 weeks after starting and that Saxenda be discontinued if at least 4% of baseline body weight has not been lost [1]. In the adolescent trial, weight regain after stopping was greater with liraglutide than with placebo [4].